Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19
Background document to the WHO Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing
14 January 2021
| COVID-19: Vaccines
Overview
This background document on the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 has been prepared by the Working Group on COVID-19 Vaccines of the Strategic Advisory Group of Experts (SAGE) on Immunization to inform SAGE deliberations. It contains the evidence summary which was considered by SAGE and served as the foundation for the WHO Interim recommendations for use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 referenced below.
Related document:
WHO Team
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ)
Number of pages
44
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/BNT162b2/background/2021.1
Copyright
